| |
Summarized by
Duk-Woo Park, MD (Asan Medical Center) |
| 1. |
Randomised
controlled trial of low dose aspirin in the prevention of cardiovascular
events and death in subjects with asymptomatic atherosclerosis.
Source: Presented by G. Fowkes at: ESC 2009 : Hot Line, Webcast |
| 2. |
A
randomized comparison of a clopidogrel high loading and maintenance
dose regimen versus standard dose and high versus low dose aspirin
in 25,000 patients with acute coronary syndromes : CURRENT OASIS
7 Trial Results.
Source: Presented by S. R. Mehta at: ESC 2009 : Hot Line, Webcast
|
| 3. |
Comparison
of Ticagrelor, the first reversible oral P2Y12 receptor antagonist,
with clopidogrel in patients with acute coronary syndromes:
results of the PLATelet inhibition and patient Outcomes (PLATO)
trial.
Source: Presented by L. C. Wallentin at: ESC 2009 : Hot Line,
Webcast |
| 4. |
A
randomized trial of dabigatran, a oral direct thrombin inhibitor,
compared to warfarin in 18,113 patients with atrial fibrillation
at high risk of stroke.
Source: Presented by S. J. Connolly at: ESC 2009 : Hot Line,
Webcast |
| 5. |
Clinical
Efficacy and Safety of Otamixaban, an Intravenous, Selective
Factor Xa Inhibitor for the Treatment of Non-ST-Elevation Acute
Coronary Syndromes: Results of SEPIA-ACS1 TIMI 42.
Source: Presented by M. Sabatine at: ESC 2009 : Hot Line, Webcast
|
| 6. |
Immediate
angioplasty versus ischemia-guided management after thrombolysis
for ST-segment elevation myocardial infarction in areas with
very long transfers: The NORDISTEMI study.
Source: Presented by S. Halvorsen at: ESC 2009 : Hot Line, Webcast
|
| 7 |
Unprotected
left main revascularization in patients with acute coronary
syndromes: GRACE left main study.
Source: Presented by G. Montalescot at: ESC 2009 : Hot Line,
Webcast |
| 8. |
Primary
angioplasty versus fibrinolysis in the very elderly: The TRIANA
Study.
Source: Presented by H. Bueno at: ESC 2009 : Hot Line, Webcast
|
| 9. |
Routine
upfront abciximab versus standard peri-procedural therapy in
patients undergoing primary percutaneous coronary intervention
for cardiogenic shock: The PRAGUE-7 Study.
Source: Presented by P. Widimsky at: ESC 2009 : Hot Line, Webcast
|
| 10. |
Randomized
trial of 3-limus agent-eluting stents with biodegradable or
permanent polymer coating: ISAR-TEST-4 study.
Source: Presented by J. Mehilli at: ESC 2009 : Hot Line, Webcast
|
| 11. |
Effects
of Valsartan on morbidity and mortality in uncontrolled hypertensive
patients with high risk of cardiovascular events (KYOTO Heart
Study).
Source: Presented by H. Matsubara at: ESC 2009 : Hot Line, Webcast
|
| 12. |
Effects
of Rolofylline in Patients with Acute Heart Failure Syndrome
and Renal Impairment: Findings from the PROTECT Study.
Source: Presented by M. Metra at: ESC 2009 : Hot Line, Webcast |
| 13. |
A
randomized evaluation of irbesartan versus placebo in patients
with Atrial Fibrillation (factorial design of ACTIVE Program).
Source: Presented by S. Yusuf at: ESC 2009 : Hot Line, Webcast |
| 14. |
Reduction
in the risk of heart failure with preventive cardiac resynchronization
therapy: MADIT-CRT Trial.
Source: Presented by A. J. Moss at: ESC 2009 : Hot Line, Webcast |
| 15. |
B-CONVINCED:
Beta-blocker CONtinuation Versus INterruption in patients with
Congestive heart failure hospitalizED for a decompensation episode.
Source: Presented by G. Jondeau at: ESC 2009 : Clinical Trial
Update, Webcast |
| 16. |
The
impact of achieved heart rate and reduction in heart rate on
cardiovascular outcomes: an analysis of the Ivabradine arm of
the BEAUTIFUL trial.
Source: Presented by K. M. Fox at: ESC 2009 : Clinical Trial
Update, Webcast |
| 17. |
Effects
of rosuvastatin on atrial fibrillation occurrence: ancillary
results of the GISSI-HF trial.
Source: Presented by A. P. Maggioni at: ESC 2009 : Clinical
Trial Update, Webcast |
| 18. |
Characteristics
of patients enrolled in the Predictors of Response to CRT (PROSPECT)
trial: comparison of subgroups according to extent of LV reverse
remodeling.
Source: Presented by RJ van Bommel at: ESC 2009 : Clinical Trial
Update, Webcast |
| 19. |
Cardiac
Resynchronization Therapy Induces Major Structural and Functional
Reverse Remodeling In Mild Heart Failure. 24 month results of
the REVERSE trial.
Source: Presented by S. Ghio at: ESC 2009 : Clinical Trial Update,
Webcast |
| 20. |
The
risk of cardiovascular event for patients treated with clopidogrel
or prasugrel in combination with a Proton Pump Inhibitor: Results
from the TRITON-TIMI 38 Trial.
Source: Presented by M. O'Donoghue at: ESC 2009 : Clinical Trial
Update, Webcast |
| 21. |
Effect
of rosiglitazone on coronary events in the RECORD study.
Source: Presented by J. J. V. McMurray at: ESC 2009 : Clinical
Trial Update, Webcast |
| 22. |
Randomized
evidence on Rosuvastatin for primary prevention in individuals
70 years of age or older. JUPITER.
Source: Presented by R. Glynn at: ESC 2009 : Clinical Trial
Update, Webcast |
| 23. |
International
impact of atherothrombotic vascular disease and events - 3-year
data from the REACH Registry.
Source: Presented by M. Alberts at: ESC 2009 : Clinical Trial
Update, Webcast |
| 24. |
Impact
of bleeding types on mortality after PCI: Results from a patient-level
pooled analysis of the REPLACE-2, ACUITY and HORIZONS trials.
Source: Presented by R. Mehran at: ESC 2009 : Clinical Trial
Update, Webcast |
| 25. |
Clinical
outcome after thrombectomy or standard angioplasty in patients
with ST elevation myocardial infarction: individual patient-data
pooled analysis of 11 randomized trials. ATTEMPT.
Source: Presented by F. Burzotta at: ESC 2009 : Clinical Trial
Update, Webcast |
| 26. |
Optimal
revascularization strategy in patients with three-vessel disease
and/or left main disease: The 2 year outcomes of the SYNTAX
Trial.
Source: Presented by AP Kappetein at: ESC 2009 : Clinical Trial
Update, Webcast |
| 27. |
Fractional
flow reserve versus angiography for guiding PCI.
Source: Presented by N. H. J. Pijls at: ESC 2009 : Clinical
Trial Update, Webcast |
| 28. |
Survival
in patients with heart failure and preserved versus impaired
left ventricular ejection fraction: an individual patient data
meta-analysis: MAGGIC.
Source: Presented by R. Doughty at: ESC 2009 : Clinical Trial
Update, Webcast |
